Cases of meningitis B dropped by 50% in the UK during the first 10 months of the world’s first national immunization program using GlaxoSmithKline’s (LSE: GSK) Bexsero.
Preliminary data, presented by Public Health England (PHE) at the International Pathogenic Neisseria Conference (INPC) in Manchester, showed the estimated effectiveness of the vaccine was 83% against meningitis B strain.
The figures also revealed the treatment was 94% effective against vaccine preventable strains of the disease and that uptake was high.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze